<DOC>
	<DOCNO>NCT01105559</DOCNO>
	<brief_summary>The purpose study evaluate long term immunogenicity produce child investigational hexavalent vaccine ( DTaP-IPV-Hep B-PRP-T ) give Study A3L15 ( NCT 00362336 ) . Primary Objective : To describe antibody long term persistence 3.5 4.5 year age follow 3 dose primary series vaccination either DTaP-IPV-Hep B-PRP-T CombAct-Hib™ + Oral poliovirus vaccine ( OPV ) + Engerix™ B vaccination 6 , 10 14 week age booster vaccination DTaP-IPV-Hep B-PRP-T CombAct-Hib™ + OPV 15-18 month</brief_summary>
	<brief_title>Antibody Persistence Healthy Children After Primary Booster DTaP-IPV-Hep B-PRP-T Vaccine Control Vaccine</brief_title>
	<detailed_description>All participant must receive primary series vaccination booster vaccination Study A3L15 ( NCT 00362336 ) . Participants receive vaccination study undergo immunologic assessment 3.5 4.5 year age .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Inclusion Criteria : Aged 3 year half day inclusion ( 42 month ± 60 day ) Informed consent form sign parent legally acceptable representative independent witness parent legal guardian illiterate . Subject parent/ legally acceptable representative able attend schedule visit comply trial procedure . Receipt primary vaccination 3 dos either DTaPIPVHep BPRPT CombActHib™ + Oral poliovirus vaccine ( OPV ) + Engerix™ B booster dose either DTaPIPVHep BPRPT CombActHib™+ OPV . Exclusion Criteria : Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede inclusion trial . Incomplete primary booster immunization trial A3L15 . Previous confirm clinical , serological , microbiological diagnosis diphtheria , tetanus , whooping cough , poliomyelitis , Haemophilus influenza b hepatitis B completion A3L15 Study . Subjects know receive diphtheria , tetanus , pertussis , Haemophilus influenza b hepatitis B vaccination completion A3L15 Study . Any vaccination within 30 day precede inclusion , except measles poliovirus ( monovalent ) contain vaccine pandemic influenza vaccine include pandemic H1N12009 strain , may receive least two week subject 's blood sample collection Blood bloodderived product receive late 3 month inclusion , receipt immunosuppressant drug within previous 3 month . Known suspect congenital acquire immunodeficiency since completion A3L15 Study . Serious chronic illness occur receipt primary booster series ( e.g . leukemia , lymphoma [ Tor B cell ] , Crohn 's disease ) . Known suspected subject seroconversion human immunodeficiency virus ( HIV ) hepatitis C seropositivity since completion A3L15 Study . Febrile ( temperature ≥ 38.0°C ) acute , moderate severe systemic illness day inclusion .</criteria>
	<gender>All</gender>
	<minimum_age>41 Months</minimum_age>
	<maximum_age>43 Months</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Diphtheria</keyword>
	<keyword>Tetanus</keyword>
	<keyword>Whooping cough</keyword>
	<keyword>Hepatitis B</keyword>
	<keyword>Poliomyelitis</keyword>
	<keyword>Diphtheria-Tetanus-acellular Pertussis Vaccines</keyword>
</DOC>